Resources for AMDI Fast PCR

The Fast PCR Mini Respiratory Panel detects and differentiates SARS-CoV-2, Influenza A, Influenza B, and respiratory syncytial virus (RSV) nucleic acids from a single anterior nasal swab specimen obtained from individuals with signs and symptoms of respiratory tract infection.

Yes. The AMDI Fast PCR Instrument and Fast PCR Mini Respiratory Panel are FDA 510(k) cleared and CLIA waived for point-of-care use.

When respiratory results are available while the patient is still present, care teams can discuss findings, document the plan, and manage next steps during the original encounter instead of relying on delayed follow-up workflows.

AMDI Fast PCR pairs a familiar anterior nasal swab with a focused respiratory RT-PCR panel in a workflow designed for point-of-care settings. The goal is to help teams move from sample collection to result review to next-step planning without adding unnecessary workflow complexity.

AMDI Fast PCR is CLIA waived and designed for point-of-care use by operators in accordance with the Instructions for Use.

Yes. AMDI Fast PCR is designed with a compact, stackable module format. Sites can stack up to four modules to support up to four tests running at the same time.

AMDI Fast PCR is designed to provide molecular respiratory results during the patient visit, which may help reduce reliance on delayed send-out testing workflows when clinically appropriate.

AMDI Fast PCR is built with connected workflow capabilities that help respiratory results move from instrument to the next operational step. Automatic data capture and connected result handling can help reduce manual entry burden and support cleaner information flow.

Yes. Additional assays, including Strep A and sexually transmitted infection testing, are currently in development. Availability and claims will depend on future regulatory clearance or authorization.